Rod Raynovich Blog | Talkmarkets | Page 1
CEO of Raygent Associates
Contributor's Links: Raygent

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ... more

Articles

Latest Posts
1 to 16 of 253 Posts
1 2 3 ... 16
Biotech Stocks Are Poised For Another Run Over July 2020 Highs
A momentum market can be hard to trade and that is why you need to always have core positions like funds and ETFs.
Biotech Stock Playbook In A Choppy Momentum Market
Biotech stocks peaked in mid-July but we have assumed a fourth quarter rally driven by clinical news in oncology and important scientific breakthroughs in diagnostic testing for coronavirus and COVID vaccine data.
Biotech Stocks Are Lagging, Position Your Portfolio For A Q4 Rally With The XBI
Technology stocks dominate gains over six weeks and lead YTD; cloud software, semiconductors and FAANG.
Tough Time To Trade Biotech Stocks, Is The Momentum Market Easing?
Until a new stimulus package emerges and coronavirus transmissions get under control stocks will remain volatile despite raging bullish sentiment.
Speculative Rally In Biotech Today, Is The Correction Over Already?
The economy and the market wants solutions to the pandemic and biotech seems to have breaking news on therapies and vaccines for traders daily.
Biotech Traders Will Face Strong Headwinds
A good day for the market and Biotech IBB up 2.67%, Semis Very Hot SMH up 4.03%.
Biotech Portfolio Review: What To Do Next?
Your biotech portfolio is probably up at least 10% YTD because the IBB is up ~17% and the XBI up 18.35%. Do you raise cash or go more defensive with the life science positions you own?
Coronavirus Stocks: Take A Breather - The Easy Trades Have Been Done
The coronavirus trade is not over because COVID Cases are spiking and the scientific news buffets stocks every day. The gains since mid-March are huge so that adding to existing positions in your portfolio will become more difficult.
Volatile Week For Coronavirus Stocks: COVID Vaccines Are In Focus
Friday was a risk-off day for biotech stocks as the XBI​ took a 3.28% hit on profit taking and concerns that the pandemic could drag on through the summer.
What’s Next For Coronavirus Stocks? Diagnostics Are The Near Term Focus…
Dexamethasone data offers hope for more severe cases of COVID infection.
Coronavirus Stock Scoreboard May 2020
Biotech stocks closed up across the board last Friday despite a choppy week.
What’s Next For The Biotech Bull Market? Are You A Trader Or An Investor?
Despite the economic pains of the pandemic, investors are driven to life science companies in the news with potential solutions for COVID-19. The potential for a COVID-19 vaccine or a new viral diagnostic product has been the focus of the market.
Another Good Week For Biopharma And Diagnostics Stocks: Innovation Is Driving Gains
As the market moves with COVID epidemiological data many stocks took a hit on questionable or incomplete news from the WHO on a clinical study in China on Remdesivir; Gilead Sciences stock took a hit on Thursday from $82 but recovered Friday at $79.
Volatile Coronavirus Biotech Stock Plays
Here are many of the well-followed life science stocks that are in the news with diagnostics, drugs and vaccines that may have an impact on the COVD-19 pandemic.
Biotech Movers On A Roller Coaster Week As Coronavirus Speculation Ramps Up
Today was a good day to nibble on positions and check your portfolio for needed re-balancing. As you know by now all major indices soared with the NASDAQ up 8.11% to 7418
Innovation Drives Biotech Stocks-time To Nibble For Longer Term
Biotech and Life Science stocks showed some green on Friday and some themes emerged that are positive were it not for the fear factor and undercurrent of U.S. politics confusing the real situation.
1 to 16 of 253 Posts
1 2 3 ... 16